Table 1. Transfer of diabetes.
| Time posttransfer, weeks
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transgenic mice group | n | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 1 | 10 | 0/10 | 0/10 | 6/10 | 9/10 | 9/10 | 10/10 | ||||||
| 2 | 9 | 0/9 | 0/9 | 0/9 | 0/9 | 0/9 | 0/9 | 0/9 | 1/9 | 1/9 | 1/9 | 4/9 | 8/9 |
| 3 | 9 | 0/9 | 0/9 | 0/9 | 0/9 | 2/9 | 8/9 | 8/9 | 8/9 | 8/9 | 9/9 | ||
| 4 | 10 | 0/10 | 0/10 | 0/10 | 1/10 | 1/10 | 2/10 | 2/10 | 3/10 | 4/10 | 4/10 | 4/10 | 4/10 |
| 5 | 10 | 0/10 | 0/10 | 2/10 | 2/10 | 2/10 | 2/10 | 3/10 | 3/10 | 3/10 | 4/10 | 4/10 | 4/10 |
Splenic T cells (10 × 106) from 6- to 7-month-old nondiabetic transgenic mice (line 4) from different groups (1–5) were transferred to NOD-SCID recipient mice, and diabetes development was monitored for 12 weeks posttransfer. Results represent the number of mice that develop diabetes over the total number of mice. Frequency and onset of diabetes in NOD-SCID recipient mice were similar when spleen cells from line 45 were transferred.